丙咪嗪,临床注释,变异和临床注释数据

id	等位基因	注释文本
52	*6	The CYP2D66 allele is assigned as a no function allele by CPIC. Patients carrying the 6 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.
51	*5	The CYP2D65 allele is assigned as a no function allele by CPIC. Patients carrying the 5 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.
50	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients carrying the 4 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.
49	*3	The CYP2D63 allele is assigned as a no function allele by CPIC. Patients carrying the 3 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.
48	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with alleles that result in a normal metabolizer phenotype may have a decreased risk of experiencing side effects when treated with imipramine as compared to patients carrying two decreased or no function alleles or a decreased function allele in combination with a no function allele. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.

等位基因

注释文本

The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.

The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.

The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.

The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.

The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a decreased risk of experiencing side effects when treated with imipramine as compared to patients carrying two decreased or no function alleles or a decreased function allele in combination with a no function allele. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.

id	证据的ID	总结
14662	1184467243	CYP2D6 3 + 4 + 5 + 6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.
14661	1183617418	CYP2D6 4/4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 1/1.
14660	1183683984	CYP2D6 poor metabolizers is associated with side effects when treated with imipramine.
14659	PA166104972	Annotation of DPWG Guideline for imipramine and CYP2D6
14658	PA166104999	Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6

证据的ID

总结

14662

1184467243

CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.

14661

1183617418

CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.

14660

1183683984

CYP2D6 poor metabolizers is associated with side effects when treated with imipramine.

14659

PA166104972

Annotation of DPWG Guideline for imipramine and CYP2D6

14658

PA166104999

Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6

id	类型	评论
104	Update	Added DPWG guideline as evidence
103	Update	CA score added as part of scoring system release. LOE assigned following curator review.
102	Update	Added CPIC guideline and 3, 5 and *6 alleles to CA. Edited phenotype descriptions.
101	Create	Created

类型

104

Update

Added DPWG guideline as evidence

103

Update

CA score added as part of scoring system release. LOE assigned following curator review.

102

Update

Added CPIC guideline and *3, *5 and *6 alleles to CA. Edited phenotype descriptions.

101

Create